Can I read Rogaratinib vs. Chemotherapy in Urothelial Cancer on EtoBox?

Rogaratinib vs. Chemotherapy in Urothelial Cancer by zainab is a document available to read on EtoBox.

What is Rogaratinib vs. Chemotherapy in Urothelial Cancer about?

The FORT-1 trial evaluated the efficacy and safety of rogaratinib, an FGFR inhibitor, compared to chemotherapy in patients with advanced urothelial carcinoma who had FGFR mRNA overexpression. Results showed comparable overall response rates and median overall survival between the two treatments, leading to the conclusion that rogaratinib has manageable safety and efficacy. Exploratory analysis indicated that patients with FGFR3 DNA alterations may benefit more from rogaratinib, suggesting a need for further

Author

zainab

Language

EN